SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES
🇮🇷Iran
- Country
- 🇮🇷Iran
- Ownership
- Private
- Established
- 1961-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.sbmu.ac.ir/
Hemodialysis-Induced Blood Pressure Change In End-Stage Renal Disease
Completed
- Conditions
- Hemodialysis
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 52
- Registration Number
- NCT04933006
- Locations
- 🇮🇷
SBMU, Tehran, Iran, Islamic Republic of
Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation
Not Applicable
Recruiting
- Conditions
- Kidney Transplant; Complications
- Interventions
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT04918407
- Locations
- 🇮🇷
Labbafinezhd Hospital, Tehran, Iran, Islamic Republic of
🇮🇷SBMU, Tehran, Iran, Islamic Republic of
Comparison of Safety and Efficacy of de Novo Everolimus
Not Applicable
Completed
- Conditions
- Cytomegalovirus Infections
- Interventions
- Drug: Sandimmun (Neoral) dose plus cellcept
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT04906304
- Locations
- 🇮🇷
Nooshin Dalili, Tehran, Iran, Islamic Republic of
Relationship Between CT- Value With Prognosis in COVID-19 Patients
Completed
- Conditions
- COVID-19
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT04902157
- Locations
- 🇮🇷
SBMU, Tehran, Iran, Islamic Republic of
🇮🇷Nooshin Dalili, Tehran, Iran, Islamic Republic of
Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
Phase 2
- Conditions
- Retinitis Pigmentosa
- Interventions
- Drug: Prescribe placebo tablets
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT04864496
- Locations
- 🇮🇷
Ophthalmic Research Center, Tehran, Iran, Islamic Republic of
Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients
Not Applicable
- Conditions
- COVID-19Respiratory Distress SyndromeSurface-Active Agents
- Interventions
- Drug: exogenous surfactant
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT04847375
Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR
Phase 2
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Drug: receive 4 monthly IVB injections and then rescue IVBDrug: PRP groupDrug: IVB injections and a modified laser
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 105
- Registration Number
- NCT04800679
- Locations
- 🇮🇷
Ophthalmic Research Center, Tehran, Iran, Islamic Republic of
The Effect of a Healthy Diet Containing Flaxseed and Olive Oil on Cardiovascular Disease Risk Markers
Not Applicable
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Other: Dietary Intervention
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT04767230
- Locations
- 🇮🇷
Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of
Ezrin Peptide (HEP-1) for Treatment of Coronavirus Disease (COVID-19) Infection
Phase 1
- Conditions
- Corona Virus InfectionCovid19Treatment
- Interventions
- Drug: PlaceboDrug: Human Ezrin Peptide 1 (HEP1)
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT04627233
- Locations
- 🇮🇷
Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of
the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19
Phase 2
- Conditions
- Covid19
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT04521400